Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUMORNATOR II
NCT07142967Recruiting
- Sponsor
- NYU Langone Health
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Open-label, single-arm trial in prostate cancer (PCa), sponsored by NYU Langone Health. Primary endpoint: Late radiation-associated genitourinary and gastrointestinal toxicity at 24 months. Started Aug 2025; status: recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07142967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07142967.